Author

Bidan Huang 1

1 AbbVie

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

ADALIMUMAB ACHIEVES COMPLETE REMISSION AT 52 WEEKS IN JAPANESE PATIENTS WITH INTESTINAL BEHÇET'S DISEASE

Fumihito Hirai, Satoshi Tanida, Nagamu Inoue, Makoto Naganuma, Anne Camez, Bidan Huang, Vipin Arora, Morio Ozawa, Toshifumi Hibi, Roopal B Thakkar

ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN'S DISEASE

William Sandborn, James D Lewis, Julian Panés, Edward V. Loftus, Jr, Geert R. D'Haens, ZHUQING YU, Bidan Huang, Ana P. Lacerda, Aileen L Pangan, Brian G. Feagan

BURDEN OF DISEASE IN PAEDIATRIC PATIENTS WITH MODERATE VERSUS SEVERE CROHN’S DISEASE IN THE IMAGINE 1 TRIAL

Frank Ruemmele, Jeffrey S Hyams, Joel Rosh, Marla C. Dubinsky, James Markowitz, Anne Griffiths, Dan Turner, Samantha Eichner, Andreas Lazar, Anne M. Robinson, Bidan Huang, Roopal B Thakkar

CLINICAL AND QUALITY ATTRIBUTE CONSISTENCY FOR A GLYCOSYLATED MONOCOLONAL ANTIBODY THERAPY (ADALIMUMAB)

TEOTONIO ALBUQUERQUE, Amy Varga, Bidan Huang, Michael Naill, Paul Tebbey

CORRELATION OF BIOMARKERS OF INFLAMMATION WITH CLINICAL AND ENDOSCOPIC ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: DATA FROM CELEST

Jean-Frederic Colombel, Laurent Peyrin-Biroulet, Silvio Danese, Simon Travis, Gerald Dryden, Robert Hardi, Michael S Epstein, Wen Zhou, Fabio Cataldi, Bidan Huang, Ana Paula Lacerda, Julian Panés

DIFFERENT METHODOLOGIES FOR DETERMINING MAYO SCORE IN CLINICAL STUDIES CAN INFLUENCE DISEASE ACTIVITY ASSESSMENTS IN ULCERATIVE COLITIS

Subrata Ghosh, William Sandborn, Julian Panés, Geert R. D'Haens, Nattanan Reilly, Andreas Lazar, Bidan Huang, Anne M. Robinson, Roopal B Thakkar

EFFICACY AND SAFETY OF ADALIMUMAB IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Baili CHEN, Xiang Gao, Jie Zhong, Jianlin Ren, Xuan Zhu, Zhanju Liu, Kaichun Wu, Jasmina Kalabic, Bidan Huang, Thao Doan, Anne M. Robinson, Minhu Chen

EFFICACY AND SAFETY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 2B STUDY U-ACHIEVE

William Sandborn, Subrata Ghosh, Julian Panés, Stefan Schreiber, Geert R. D'Haens, Satoshi Tanida, Jesse Siffledeen, Jose Enejosa, Wen Zhou, Ahmed A. Othman, Bidan Huang, Peter D.R. Higgins

EFFICACY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, WITH OR WITHOUT PREVIOUS TREATMENT FAILURE OF BIOLOGIC THERAPY: DATA FROM THE DOSE-RANGING PHASE 2B STUDY U-ACHIEVE

Remo Panaccione, Geert R. D'Haens, William Sandborn, Subrata Ghosh, Stefan Schreiber, Satoshi Tanida, Wen Zhou, Fabio Cataldi, David Pugatch, Bidan Huang, Wangang Xie, Peter Higgins

Item 1 - 10 / 26
1
2 3